Antibodies

Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

GSK 1070806 (anti-IL-18) is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).

Indatuximab (anti-Syndecan-1) is an antibody against Syndecan-1.

Indatuximab (anti-Syndecan-1) is an antibody against Syndecan-1.

Indatuximab (anti-Syndecan-1) is an antibody against Syndecan-1.

Indatuximab (anti-Syndecan-1) is an antibody against Syndecan-1.

Itepekimab (anti-IL-33) is a monoclonal antibody of IL-33. Itepekimab (anti-IL-33) reduces airway inflammation and related tissue damage in previous clinical studies. Itepekimab (anti-IL-33) has potential application in asthma, chronic obstructive

Itepekimab (anti-IL-33) is a monoclonal antibody of IL-33. Itepekimab (anti-IL-33) reduces airway inflammation and related tissue damage in previous clinical studies. Itepekimab (anti-IL-33) has potential application in asthma, chronic obstructive

Itepekimab (anti-IL-33) is a monoclonal antibody of IL-33. Itepekimab (anti-IL-33) reduces airway inflammation and related tissue damage in previous clinical studies. Itepekimab (anti-IL-33) has potential application in asthma, chronic obstructive